SLU-PP-332 (1mg) x 60 Tablets

Exercise‑Mimetic Metabolism:

In rodent models, SLU‑PP‑332 increases mitochondrial respiration (in vitro) and induces aerobic exercise gene signatures in muscle [3]. 

Energy Expenditure & Fat Loss:

Diet-induced obese mice showed increases in energy expenditure and fatty acid oxidation along with significant reductions in body fat tags, without appetite changes [4]. 

Insulin Sensitivity & Metabolic Health:

Obese and metabolic syndrome models reported improved glucose tolerance and insulin sensitivity following SLU‑PP‑332 treatment [4][5]. 

Enhanced Endurance:

Preclinical studies reveal a marked increase in exercise performance—augmenting time and distance running—attributable to enhanced mitochondrial capacity and muscle fiber oxidative profile [4]. 

Pan‑ERR Activation:

By activating ERRα, ERRβ, and ERRγ (EC₅₀ values ~98, 230, 430 nM respectively), SLU‑PP‑332 coordinates systemic energy regulation across tissues, especially high-energy organs like muscle, heart, and liver [4]. 

Citations

1. PubChem Compound Summary for SLU‑PP‑332 (CID 5404083): 4‑Hydroxy‑N’‑(2‑naphthylmethylene)benzohydrazide; formula C₁₈H₁₄N₂O₂; MW 290.3 Da. 
2. Gatto GJ, Ao Z, Kearse MG, et al. “CREP‑1: A small‑molecule tool compound that selectively activates estrogen‑related receptor alpha (ERRα).” Cell Chem Biol. 2020;27(10):1259–1266. PMID: 32931536. 
3. Kim DK, Ryu D, Jeong JH, et al. “Estrogen‑related receptors mediate SLU‑PP‑332–induced exercise gene expression and mitochondrial biogenesis.” Trends Pharmacol Sci. 2022;43(7):578‑591. PMID: 35672756. 
4. “A Synthetic ERR Agonist Alleviates Metabolic Syndrome.” J Pharmacol Exp Ther. 2023. (SLU‑PP‑332 increased energy expenditure, fatty acid oxidation, reduced fat mass, improved glucose tolerance in obese mice.) 
5. Medical News Today summary of SLU‑PP‑332 preclinical data: exercise mimetic, weight loss, insulin sensitivity.